Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. on September 10, 2021. The filing serves as a report of a material corporate action regarding the Company's American Depositary Receipt (ADR) program. The Company is a foreign private issuer based in Kfar Saba, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a capital structure adjustment and does not contain financial performance data.
Material Changes
The primary material change announced is a 4:1 reverse ratio change to the Company's ADR program. Key details include:
- Ratio Adjustment: Each American Depositary Share (ADS) will represent 400 ordinary shares, increased from the previous 100 ordinary shares.
- Effective Date: The change is anticipated to take effect on September 24, 2021.
- Exchange Mechanism: ADS holders must surrender old ADSs to BNY Mellon at a rate of one new ADS for every four old ADSs held.
- Fractional Shares: No fractional ADSs will be issued; cash will be paid in lieu of fractional amounts.
- Ownership Impact: The change will not reduce any holder's ownership percentage, except for minor adjustments due to fractional share treatment, and will not alter the Company's total share capital.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, or specific risk factors beyond the mechanics of the ADR ratio change. No unusual items or contingencies were disclosed in this text.
Key Facts for Investor Verification
- Verify the exact effective date of the 4:1 ADR ratio change (anticipated September 24, 2021).
- Confirm the procedure for surrendering old ADSs to BNY Mellon to avoid missing the exchange deadline.
- Check the calculation for cash payments in lieu of fractional ADSs if holding a number of shares not divisible by four.
- Review the Company's Form 20-F for the most recent audited financial statements, as this filing contains no financial data.